CO5600999A2 - Composiciones farmaceuticas que comprenden inhibidores de valsartan y endopeptidasa neutra - Google Patents
Composiciones farmaceuticas que comprenden inhibidores de valsartan y endopeptidasa neutraInfo
- Publication number
- CO5600999A2 CO5600999A2 CO04076723A CO04076723A CO5600999A2 CO 5600999 A2 CO5600999 A2 CO 5600999A2 CO 04076723 A CO04076723 A CO 04076723A CO 04076723 A CO04076723 A CO 04076723A CO 5600999 A2 CO5600999 A2 CO 5600999A2
- Authority
- CO
- Colombia
- Prior art keywords
- valsartan
- neutral endopeptidase
- pharmaceutical compositions
- include inhibitors
- pharmaceutically acceptable
- Prior art date
Links
- 102000003729 Neprilysin Human genes 0.000 title abstract 3
- 108090000028 Neprilysin Proteins 0.000 title abstract 3
- 239000004072 C09CA03 - Valsartan Substances 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 title abstract 2
- 229960004699 valsartan Drugs 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000005557 antagonist Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/47—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
- C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
- C07C215/10—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with one amino group and at least two hydroxy groups bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US34966002P | 2002-01-17 | 2002-01-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO5600999A2 true CO5600999A2 (es) | 2006-01-31 |
Family
ID=23373410
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO04076723A CO5600999A2 (es) | 2002-01-17 | 2004-08-06 | Composiciones farmaceuticas que comprenden inhibidores de valsartan y endopeptidasa neutra |
Country Status (29)
Country | Link |
---|---|
EP (1) | EP1467728B1 (enIt.pdf) |
JP (2) | JP4820056B2 (enIt.pdf) |
KR (2) | KR100984939B1 (enIt.pdf) |
CN (2) | CN102091330B (enIt.pdf) |
AT (1) | ATE370732T1 (enIt.pdf) |
AU (1) | AU2003206738C1 (enIt.pdf) |
BE (1) | BE2016C025I2 (enIt.pdf) |
BR (2) | BRPI0306907B8 (enIt.pdf) |
CA (1) | CA2472399C (enIt.pdf) |
CO (1) | CO5600999A2 (enIt.pdf) |
CY (2) | CY1106959T1 (enIt.pdf) |
DE (1) | DE60315795T2 (enIt.pdf) |
DK (1) | DK1467728T3 (enIt.pdf) |
EC (1) | ECSP045190A (enIt.pdf) |
ES (1) | ES2290429T3 (enIt.pdf) |
FR (1) | FR16C0019I2 (enIt.pdf) |
HU (1) | HUS1600024I1 (enIt.pdf) |
IL (2) | IL162661A0 (enIt.pdf) |
LU (1) | LU93074I2 (enIt.pdf) |
MX (1) | MXPA04006917A (enIt.pdf) |
NL (1) | NL300811I2 (enIt.pdf) |
NO (2) | NO333191B1 (enIt.pdf) |
NZ (1) | NZ533968A (enIt.pdf) |
PL (1) | PL212318B1 (enIt.pdf) |
PT (1) | PT1467728E (enIt.pdf) |
RU (1) | RU2334513C3 (enIt.pdf) |
SI (1) | SI1467728T1 (enIt.pdf) |
WO (1) | WO2003059345A1 (enIt.pdf) |
ZA (1) | ZA200405117B (enIt.pdf) |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006000564A1 (en) * | 2004-06-23 | 2006-01-05 | Solvay Pharmaceuticals Gmbh | Pharmaceutical compositions comprising nep-inhibitors, inhibitors of the endogenous endothelin producing system and at1-receptor antagonists |
US20080102120A1 (en) | 2004-12-24 | 2008-05-01 | Miha Vrbinc | Solid Pharmaceutical Composition Comprising Valsartan |
MY146830A (en) * | 2005-02-11 | 2012-09-28 | Novartis Ag | Combination of organic compounds |
WO2007045663A2 (en) * | 2005-10-19 | 2007-04-26 | Novartis Ag | Combination of an ati receptor antagonist and a np inhibitor fro treating ia hypertension and heartfailure |
WO2007051007A2 (en) * | 2005-10-28 | 2007-05-03 | Novartis Ag | Combination of antihypertensives with cholesterol-lowering agent |
AR057882A1 (es) * | 2005-11-09 | 2007-12-26 | Novartis Ag | Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra |
WO2007106708A2 (en) * | 2006-03-10 | 2007-09-20 | Novartis Ag | Combinations of the angiotensin ii antagonist valsartan and the nep inhibitor daglutril |
CZ300801B6 (cs) * | 2006-06-07 | 2009-08-12 | Helvetia Pharma A.S. | Kompozice s valsartanem v pevných lékových formách |
SI2121578T1 (sl) | 2007-01-12 | 2016-12-30 | Novartis Ag | Postopek za pripravo 5-bifenil-4-amino-2-metil pentanojske kisline |
GB0708507D0 (en) | 2007-05-02 | 2007-06-13 | Queen Mary & Westfield College | Substituted phosphonates and their use |
SI3067043T1 (sl) | 2007-11-06 | 2023-04-28 | Novartis Ag | Farmacevtski sestavki na osnovi superstruktur antagonista/blokatorja angiotenzinskega receptorja (ARB) in zaviralca nevtralne endopeptidaze (NEP) |
CN101774941A (zh) | 2009-01-13 | 2010-07-14 | 浙江九洲药业股份有限公司 | 2-酰基氨基-3-联苯基丙酸的制备及拆分方法 |
KR101442897B1 (ko) | 2009-05-28 | 2014-09-23 | 노파르티스 아게 | 네프릴리신 억제제로서의 치환된 아미노프로피온산 유도체 |
CN102448928B (zh) | 2009-05-28 | 2014-10-01 | 诺华股份有限公司 | 作为中性溶酶(neprilysin)抑制剂的取代的氨基丁酸衍生物 |
JO2967B1 (en) | 2009-11-20 | 2016-03-15 | نوفارتس ايه جي | Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors |
US8835668B2 (en) | 2010-08-23 | 2014-09-16 | Novartis Ag | Process for the preparation of intermediates for the manufacture of NEP inhibitors |
US8673974B2 (en) | 2010-11-16 | 2014-03-18 | Novartis Ag | Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors |
CN108685889A (zh) * | 2012-08-24 | 2018-10-23 | 诺华股份有限公司 | 用于治疗特征为心房增大或重构的疾病的nep抑制剂 |
CA2900226A1 (en) | 2013-02-14 | 2014-08-21 | Novartis Ag | Substituted bisphenyl butanoic acid derivatives as nep inhibitors with improved in vivo efficacy |
DK2956464T3 (en) | 2013-02-14 | 2018-07-16 | Novartis Ag | Substituted bisphenyl-butane phosphonic acid derivatives as NEP (neutral endopeptidase) inhibitors |
CN104230865B (zh) * | 2013-06-13 | 2018-01-09 | 上海翰森生物医药科技有限公司 | 联芳基取代的4‑氨基丁酸衍生物及其制备方法和用途 |
EP3038653A1 (en) | 2013-08-26 | 2016-07-06 | Novartis AG | New use |
PT3626270T (pt) | 2013-08-26 | 2024-01-11 | Novartis Ag | Tratamento de doenças cardiovasculares |
WO2016029828A1 (zh) * | 2014-08-27 | 2016-03-03 | 上海翰森生物医药科技有限公司 | AHU-377结晶型游离酸、半钙盐、α﹣苯乙胺盐及其制备方法和应用 |
WO2016037098A1 (en) * | 2014-09-04 | 2016-03-10 | Concert Pharmaceuticals, Inc. | Deuterated sacubitril |
WO2016037552A1 (zh) * | 2014-09-09 | 2016-03-17 | 上海翰森生物医药科技有限公司 | 结晶型ARB-NEPi复合物及其制备方法和应用 |
CN105503760A (zh) * | 2014-10-10 | 2016-04-20 | 上海翰森生物医药科技有限公司 | 结晶型ARB-NEPi双阳离子复合物及其制备方法和应用 |
HUE046278T2 (hu) | 2014-11-14 | 2020-02-28 | Zentiva Ks | Módszer AHU-377 gyógyszerészetben alkalmazható formáinak elõállítására, izolálására és tisztítására |
WO2016086798A1 (zh) * | 2014-12-03 | 2016-06-09 | 上海翰森生物医药科技有限公司 | Nep抑制剂结晶型游离酸、钙盐多晶型及其制备方法和应用 |
US9957240B2 (en) * | 2014-12-08 | 2018-05-01 | Crystal Pharmatech Co., Ltd | Crystalline forms of trisodium supramolecular complex comprising valsartan and AHU-377 and methods thereof |
CN105693543B (zh) * | 2014-12-15 | 2018-08-10 | 四川海思科制药有限公司 | 沙库比曲类衍生物、其药物组合物、制备方法及用途 |
CN104826115A (zh) * | 2015-04-19 | 2015-08-12 | 浙江巨泰药业有限公司 | 一种抗心衰药物组合物及其制备方法 |
CN106138069A (zh) * | 2015-04-21 | 2016-11-23 | 刘春丽 | 作为治疗来自非角化复层上皮组织的不适的局部药剂的1-二仲丁基膦酰基戊烷 |
HRP20230480T1 (hr) | 2015-05-11 | 2023-07-21 | Novartis Ag | Režim doziranja sakubitrila i valsartana za liječenje zatajenja srca |
WO2016193883A1 (en) | 2015-05-29 | 2016-12-08 | Novartis Ag | Sacubitril and valsartan for treating metabolic disease |
WO2017006254A1 (en) | 2015-07-08 | 2017-01-12 | Novartis Ag | Drug combination comprising an angiotensin ii receptor antagonist, a neutral endopeptidase inhibitor and a mineralcorticoid receptor antagonist |
WO2017012600A1 (en) | 2015-07-20 | 2017-01-26 | Zentiva, K.S. | A pharmaceutical composition containing valsartan and sacubitril and methods for preparation and stabilization thereof |
CN106397249A (zh) * | 2015-08-03 | 2017-02-15 | 深圳信立泰药业股份有限公司 | 一种高稳定性lcz696结晶粉末及其制备方法 |
WO2017037577A1 (en) | 2015-08-28 | 2017-03-09 | Novartis Ag | New use |
WO2017036420A1 (zh) * | 2015-09-06 | 2017-03-09 | 常州方楠医药技术有限公司 | 含沙库比曲和缬沙坦的药用组合物及其制备方法 |
CN105348209B (zh) * | 2015-12-09 | 2017-12-26 | 浙江天宇药业股份有限公司 | 一种抗心衰药lcz696的制备方法 |
MX2018007129A (es) | 2015-12-11 | 2018-11-09 | Zentiva Ks | Formas solidas de ester etilico del acido (2r,4s)-5-(bifenil-4-il) -4-[(3-carboxipropionil)amino]-2-metil-pentanoico, sus sales y un metodo de preparacion. |
US10722471B2 (en) | 2016-02-03 | 2020-07-28 | Novartis Ag | Galenic formulations of organic compounds |
AU2017215530B2 (en) | 2016-02-03 | 2019-09-12 | Novartis Ag | Galenic formulations of organic compounds |
EP3524250A4 (en) | 2016-10-08 | 2020-05-20 | Wuhan LL Science And Technology Development Co., Ltd. | PHARMACEUTICAL COMPOSITION |
WO2018211479A1 (en) | 2017-05-19 | 2018-11-22 | Lupin Limited | Stabilized compositions of angiotensin ii inhibitors and neutral endopeptidase inhibitors and process for preparation thereof |
US11382866B2 (en) | 2017-07-06 | 2022-07-12 | Mankind Pharma Ltd. | Fixed dose pharmaceutical composition of valsartan and sacubitril |
WO2019020706A1 (en) | 2017-07-28 | 2019-01-31 | Synthon B.V. | PHARMACEUTICAL COMPOSITION COMPRISING SACUBITRIL AND VALSARTAN |
UY38072A (es) | 2018-02-07 | 2019-10-01 | Novartis Ag | Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos |
CN110237071B (zh) | 2018-03-09 | 2022-03-22 | 武汉朗来科技发展有限公司 | 药物制剂及其应用 |
KR20210032437A (ko) | 2018-08-23 | 2021-03-24 | 노파르티스 아게 | 심부전의 치료를 위한 신규한 약제학적 용도 |
WO2020039394A1 (en) | 2018-08-24 | 2020-02-27 | Novartis Ag | New drug combinations |
KR20200020746A (ko) | 2020-02-07 | 2020-02-26 | 보령제약 주식회사 | 하이브리드 화합물 및 그 제조방법 |
KR20210101164A (ko) | 2020-02-07 | 2021-08-18 | 보령제약 주식회사 | 하이브리드 화합물 및 그 제조방법 |
WO2021158084A1 (ko) * | 2020-02-07 | 2021-08-12 | 보령제약 주식회사 | 하이브리드 화합물 및 그 제조방법 |
KR20210120560A (ko) | 2020-03-27 | 2021-10-07 | 주식회사 유영제약 | 고함량의 주성분을 포함하는 정제 및 그 제조방법 |
KR20220091767A (ko) | 2020-12-24 | 2022-07-01 | 주식회사 보령 | 사쿠비트릴 발사르탄 하이브리드 화합물 또는 그 약제학적으로 허용되는 염을 유효성분으로 포함하는 약제학적 조성물 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992013564A1 (en) * | 1991-02-06 | 1992-08-20 | Schering Corporation | Combination of an angiotensin ii antagonist or renin inhibitor with a neutral endopeptidase inhibitor |
US5217996A (en) * | 1992-01-22 | 1993-06-08 | Ciba-Geigy Corporation | Biaryl substituted 4-amino-butyric acid amides |
CA2168066A1 (en) * | 1995-02-08 | 1996-08-09 | James R. Powell | Treatment of hypertension and congestive heart failure |
JP2003533440A (ja) * | 2000-04-03 | 2003-11-11 | ブリストル−マイヤーズ スクイブ カンパニー | 隔離心収縮期高血圧症を処置するバソペプチダーゼ抑制剤 |
NZ540748A (en) * | 2000-06-22 | 2007-04-27 | Novartis Ag | An oral solid pharmaceutical composition comprising valsartan and a filler in a weight ratio from 2:1 to 1:1 |
CN1216873C (zh) * | 2000-07-19 | 2005-08-31 | 诺瓦提斯公司 | 缬沙坦的盐 |
US6777443B2 (en) * | 2001-05-15 | 2004-08-17 | Novartis Ag | Dipeptide derivatives |
-
2003
- 2003-01-16 IL IL16266103A patent/IL162661A0/xx unknown
- 2003-01-16 PL PL369773A patent/PL212318B1/pl unknown
- 2003-01-16 EP EP03704413A patent/EP1467728B1/en not_active Expired - Lifetime
- 2003-01-16 MX MXPA04006917A patent/MXPA04006917A/es active IP Right Grant
- 2003-01-16 CA CA2472399A patent/CA2472399C/en not_active Expired - Lifetime
- 2003-01-16 WO PCT/EP2003/000415 patent/WO2003059345A1/en active Application Filing
- 2003-01-16 BR BRPI0306907A patent/BRPI0306907B8/pt active IP Right Grant
- 2003-01-16 KR KR1020047011124A patent/KR100984939B1/ko active IP Right Review Request
- 2003-01-16 CN CN201110029600.7A patent/CN102091330B/zh not_active Expired - Lifetime
- 2003-01-16 JP JP2003559507A patent/JP4820056B2/ja not_active Expired - Lifetime
- 2003-01-16 KR KR1020107010521A patent/KR20100057704A/ko not_active Application Discontinuation
- 2003-01-16 RU RU2004125178A patent/RU2334513C3/ru active
- 2003-01-16 AT AT03704413T patent/ATE370732T1/de active
- 2003-01-16 DE DE60315795T patent/DE60315795T2/de not_active Expired - Lifetime
- 2003-01-16 NZ NZ533968A patent/NZ533968A/en not_active IP Right Cessation
- 2003-01-16 BR BR122018015003A patent/BR122018015003B8/pt not_active IP Right Cessation
- 2003-01-16 PT PT03704413T patent/PT1467728E/pt unknown
- 2003-01-16 ES ES03704413T patent/ES2290429T3/es not_active Expired - Lifetime
- 2003-01-16 SI SI200331029T patent/SI1467728T1/sl unknown
- 2003-01-16 DK DK03704413T patent/DK1467728T3/da active
- 2003-01-16 AU AU2003206738A patent/AU2003206738C1/en active Active
- 2003-01-16 CN CNA038022680A patent/CN1615134A/zh active Pending
-
2004
- 2004-06-21 IL IL162661A patent/IL162661A/en active Protection Beyond IP Right Term
- 2004-06-28 ZA ZA2004/05117A patent/ZA200405117B/en unknown
- 2004-07-14 EC EC2004005190A patent/ECSP045190A/es unknown
- 2004-08-06 CO CO04076723A patent/CO5600999A2/es active IP Right Grant
- 2004-08-13 NO NO20043380A patent/NO333191B1/no not_active IP Right Cessation
-
2007
- 2007-10-25 CY CY20071101386T patent/CY1106959T1/el unknown
-
2011
- 2011-05-25 JP JP2011116928A patent/JP2011207898A/ja not_active Withdrawn
-
2016
- 2016-05-17 FR FR16C0019C patent/FR16C0019I2/fr active Active
- 2016-05-18 NO NO2016009C patent/NO2016009I2/no unknown
- 2016-05-18 CY CY2016013C patent/CY2016013I1/el unknown
- 2016-05-18 BE BE2016C025C patent/BE2016C025I2/nl unknown
- 2016-05-18 HU HUS1600024C patent/HUS1600024I1/hu unknown
- 2016-05-18 NL NL300811C patent/NL300811I2/nl unknown
- 2016-05-18 LU LU93074C patent/LU93074I2/fr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO5600999A2 (es) | Composiciones farmaceuticas que comprenden inhibidores de valsartan y endopeptidasa neutra | |
CY1108725T1 (el) | Συνδυασμος ανταγωνιστου-nmda και αναστολεων ακετυλοχολινεστερασης δια την θεραπειαν της νοσου alzheimer | |
DE60134349D1 (de) | Synergistische Kombinationen enthaltend einen Renininhibitor für Kardiovaskulären Erkrankungen | |
CO5680428A2 (es) | Antagonistas del receptor de trombina | |
ECSP044992A (es) | Inhibidores de la alquín-aril fosfodiesterasa-4 | |
DOP2004001052A (es) | Inhibidores heterociclil amino de 11-beta-hidroxiesteroide deshidrogenasa tipo 1 | |
AR040553A1 (es) | Combinacion que comprende un inhibidor de ibat y tratamiento terapeutico | |
ATE409485T1 (de) | Pharmazeutische zusammensetzungen inhibitoren von fab i und weitere antibiotika enthaltend | |
ECSP055745A (es) | Derivados de 1-(4-bencil-piperazin-1-il)-3-fenil-propenona | |
RS52110B (en) | DIPEPTIDIL PEPTIDASE INHIBITORS FOR TREATMENT OF DIABETES | |
UY26380A1 (es) | Inhibidores de fab i | |
ATE442145T1 (de) | Pharmazeutische zusammensetzung mit einem benzodiazepin-derivat und einem hemmer des rsv- fusionsproteins | |
ECSP045004A (es) | Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades andrógeno dependientes | |
ATE437643T1 (de) | Pharmazeutische zusammensetzung mit einem benzodiazepin-derivat und einem hemmer des rsv- fusionsproteins | |
ECSP045104A (es) | Ligandos de los receptores de los cannabinoides | |
CY1108522T1 (el) | Μεθοδος συνθεσης της περινδοπριλης και των φαρμακευτικως αποδεκτων αλατων της | |
MX2008014873A (es) | Inhibidores de metaloproteasa heterobiciclicas. | |
PA8564901A1 (es) | Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo | |
DK0715623T3 (da) | Blodpladeaggregationsinhibitorer | |
EA200401183A1 (ru) | Применение ингибиторов il-18 в качестве диагностического маркера | |
WO2003057205A3 (de) | KOMBINATION VON MTP INHIBITOREN ODER apoB-SEKRETIONS-INHIBITOREN MIT FIBRATEN ZUR VERWENDUNG ALS ARZNEIMITTEL | |
ES2194933T3 (es) | Inhibidores de la agregacion plaquetaria. | |
CR10690A (es) | Nuevos derivados de fluoreno, composiciones que los contienen y utilizacion como inhibidores de la proteina chaperona hsp90 | |
ATE287416T1 (de) | Thrombin inhibitoren | |
HRP20080546T3 (en) | Combination of an antagonist of the tp-receptors and clopidogrel |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Application granted |